Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Share-based Compensation (2020 - 2025)

Roivant Sciences' Share-based Compensation history spans 6 years, with the latest figure at $18.1 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 73.88% year-over-year to $18.1 million; the TTM value through Dec 2025 reached $240.5 million, up 20.73%, while the annual FY2025 figure was $289.0 million, 44.78% up from the prior year.
  • Share-based Compensation reached $18.1 million in Q4 2025 per ROIV's latest filing, down from $70.8 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $82.2 million in Q2 2025 to a low of $11.3 million in Q3 2021.
  • Average Share-based Compensation over 5 years is $40.3 million, with a median of $37.8 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: skyrocketed 277.78% in 2022, then plummeted 73.88% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $17.7 million in 2021, then fell by 22.46% to $13.7 million in 2022, then surged by 47.45% to $20.2 million in 2023, then skyrocketed by 243.5% to $69.4 million in 2024, then tumbled by 73.88% to $18.1 million in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Share-based Compensation are $18.1 million (Q4 2025), $70.8 million (Q3 2025), and $82.2 million (Q2 2025).